Recent Finacing
Recent Raise
Sequenta operates the LymphoSIGHT sequencing platform and ClonoSIGHT MRD clinical test, using immune-receptor sequencing to detect and quantify minimal residual disease in lymphoid cancers at ~1-in-a-million sensitivity.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors